MHC class I presented antigens from malignancies: A perspective on analytical characterization & immunogenicity

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Cancer immunotherapy has seen rapid advancements, with T cell-mediated killing of tumors being a key focus.
• Many current therapies leverage CD8+ T cell responses against tumor antigens presented by MHC Class I molecules.

Purpose of the Study:

• To review tumor antigens targeted in T cell-based therapeutic strategies.
• To discuss the rationale behind targeting MHC Class I antigens.
• To explore analytical tools for discovering MHC Class I presented peptides.

Main Methods:

• Literature review of existing research on tumor antigens and MHC Class I presentation.
• Analysis of various analytical techniques used for peptide discovery.
• Discussion of advantages and disadvantages of different approaches.

Main Results:

• Categorization of tumor antigens relevant for T cell-based therapies.
• Overview of analytical tools for identifying MHC Class I presented peptides.
• Evaluation of the strengths and limitations of current methods.

Conclusions:

• This review provides a comprehensive summary of tumor antigens and analytical tools for MHC Class I peptide discovery.
• It offers insights into the future of MHC Class I peptide exploration and biotherapeutic strategies in cancer immunotherapy.